Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus POLYCILLIN PRB.
PENICILLIN V POTASSIUM vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
250-500 mg orally every 6-8 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life.
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic